Immatics (IMTX) Competitors $6.26 +0.54 (+9.44%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.16 -0.10 (-1.61%) As of 09/5/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. TARS, OGN, ALVO, CNTA, DNLI, IBRX, AGIO, IDYA, OCUL, and HRMYShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Tarsus Pharmaceuticals (TARS), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Its Competitors Tarsus Pharmaceuticals Organon & Co. Alvotech Centessa Pharmaceuticals Denali Therapeutics ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Harmony Biosciences Immatics (NASDAQ:IMTX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability. Do insiders & institutionals have more ownership in IMTX or TARS? 64.4% of Immatics shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, IMTX or TARS? Immatics has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Does the media refer more to IMTX or TARS? In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Immatics. MarketBeat recorded 10 mentions for Tarsus Pharmaceuticals and 5 mentions for Immatics. Tarsus Pharmaceuticals' average media sentiment score of 1.58 beat Immatics' score of 1.32 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend IMTX or TARS? Immatics currently has a consensus target price of $14.67, suggesting a potential upside of 134.29%. Tarsus Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 15.68%. Given Immatics' higher possible upside, equities research analysts plainly believe Immatics is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has preferable earnings and valuation, IMTX or TARS? Immatics has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmatics$168.65M4.51$16.47M-$0.65-9.63Tarsus Pharmaceuticals$182.95M13.30-$115.55M-$2.33-24.73 Is IMTX or TARS more profitable? Tarsus Pharmaceuticals has a net margin of -31.13% compared to Immatics' net margin of -59.29%. Immatics' return on equity of -15.60% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Immatics-59.29% -15.60% -12.31% Tarsus Pharmaceuticals -31.13%-32.36%-21.04% SummaryImmatics and Tarsus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$695.27M$3.12B$5.77B$9.91BDividend YieldN/A2.29%6.71%4.52%P/E Ratio-9.6320.9775.5426.08Price / Sales4.51290.04480.4288.33Price / Cash23.4144.9736.9659.01Price / Book1.229.8611.446.09Net Income$16.47M-$53.47M$3.28B$266.14M7 Day Performance22.99%2.92%0.96%0.34%1 Month Performance-1.26%9.83%7.83%4.42%1 Year Performance-46.63%15.97%62.64%26.17% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.3125 of 5 stars$6.26+9.4%$14.67+134.3%-45.2%$695.27M$168.65M-9.63260News CoveragePositive NewsHigh Trading VolumeTARSTarsus Pharmaceuticals1.9811 of 5 stars$58.58+0.7%$66.67+13.8%+111.0%$2.47B$182.95M-25.1450News CoveragePositive NewsOGNOrganon & Co.4.7256 of 5 stars$9.40+2.3%$18.00+91.6%-51.5%$2.45B$6.40B3.494,000News CoveragePositive NewsALVOAlvotech2.4809 of 5 stars$8.07+0.2%$14.00+73.5%-26.6%$2.43B$491.98M35.091,032Short Interest ↑CNTACentessa Pharmaceuticals3.3117 of 5 stars$16.79+1.4%$31.50+87.6%+7.7%$2.25B$6.85M-9.38200Trending NewsAnalyst ForecastAnalyst RevisionDNLIDenali Therapeutics4.3458 of 5 stars$15.27-2.4%$33.62+120.1%-38.9%$2.23B$330.53M-5.45430Positive NewsIBRXImmunityBio2.7305 of 5 stars$2.34+0.4%$10.75+359.4%-30.4%$2.21B$14.74M-4.87590Positive NewsAGIOAgios Pharmaceuticals4.4124 of 5 stars$37.71-1.2%$56.33+49.4%-18.2%$2.19B$36.50M3.43390Trending NewsAnalyst ForecastOptions VolumeIDYAIDEAYA Biosciences4.2543 of 5 stars$24.55-1.5%$47.10+91.9%-27.3%$2.15B$7M-6.4880Trending NewsAnalyst ForecastAnalyst RevisionOCULOcular Therapeutix3.8385 of 5 stars$12.21-2.5%$17.20+40.9%+61.1%$2.12B$63.72M-9.54230News CoverageHRMYHarmony Biosciences4.5124 of 5 stars$36.89-2.8%$51.00+38.2%+1.2%$2.12B$714.73M11.90200News CoveragePositive News Related Companies and Tools Related Companies Tarsus Pharmaceuticals Competitors Organon & Co. Competitors Alvotech Competitors Centessa Pharmaceuticals Competitors Denali Therapeutics Competitors ImmunityBio Competitors Agios Pharmaceuticals Competitors IDEAYA Biosciences Competitors Ocular Therapeutix Competitors Harmony Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMTX Stock Alerts